Longbio Pharma

This study tested a new drug called LP-003 in 180 adults with moderate to severe seasonal allergies that were not well controlled by standard treatments like antihistamines or nasal sprays. LP-003 is a lab-made antibody that blocks IgE, a key driver of allergic reactions, and is …

This study tested a new medicine called LP-003 for people with chronic hives that still cause itching and welts even after taking allergy pills. 202 adults received the drug or a placebo as a shot under the skin. The main goal was to see if the drug could completely stop hives an…

This early-stage study tested LP-001 in 68 healthy adults aged 18-50 to see if it is safe and how the body handles it. The drug is being developed for myelodysplastic syndrome (MDS), a blood disorder. The study gave single and multiple doses to gather key information before testi…

This early-stage study tested LP-005, a potential treatment for a rare blood disease called PNH, in 68 healthy adults aged 18 to 50. The main goal was to check safety and how the drug moves through the body. Participants received either a single or multiple doses of LP-005, and r…

This early-stage study tested a new drug called LP-003 in 60 healthy adults to see if it is safe and how the body processes it. The study had two parts: one where people got a single dose, and another where they got multiple doses. The goal was to gather basic safety and drug-lev…